Arcellx, Inc.
https://arcellx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arcellx, Inc.
Gilead Doesn’t See Big M&A In Near-Term, But Eyes Next-Gen Cell Therapies
CEO Daniel O’Day highlighted Gilead’s large pipeline and relative safety from patent expirations over the next few years in the company’s Q1 earnings call.
J&J/Legend Tout Carvykti In Earlier Lines As Competitors Move In
They have new data for the CAR-T after one to three lines of multiple myeloma treatment and Phase III patient-reported outcomes data, but Gilead and Gracell are nipping at the companies’ and BMS’s heels.
BMS Forges Ahead With Next Round Of Multiple Myeloma Therapies
The drug maker provided updates at ASH on newer agents, including a GPRC5D-directed CAR-T therapy, a member of the CELMoD class and its entry into an increasingly crowded BCMA bispecific ring.
A Neato Cell: Data Show Favorable Efficacy, Toxicity For Arcellx/Gilead Myeloma CAR-T
Anito-cel showed strong efficacy in heavily pretreated patients despite characteristics predicting poorer performance, but none of the atypical neurotoxicities that have appeared with other BCMA CAR-Ts.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice